中国报告大厅网讯,2025年5月23日,中国医药产业迎来历史性时刻——恒瑞医药正式登陆港交所。作为国内首个实现从仿制药向创新药全面转型的标杆企业,此次港股上市不仅为公司全球化布局注入新动能,更标志着中国医药行业在创新驱动下的高质量发展进入新阶段。通过引入国际资本、优化研发管线及加速国际化进程,这家深耕医药领域近三十年的企业正以全新姿态开启全球市场征程。 一、研发投入驱动创新药矩阵持续扩容 中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.